[HTML][HTML] ERK/MAPK signalling pathway and tumorigenesis
YJ Guo, WW Pan, SB Liu… - Experimental and …, 2020 - spandidos-publications.com
Mitogen‑activated protein kinase (MAPK) cascades are key signalling pathways that
regulate a wide variety of cellular processes, including proliferation, differentiation …
regulate a wide variety of cellular processes, including proliferation, differentiation …
Marginal-zone lymphomas
Marginal-Zone Lymphomas The third most common lymphoma, MZL is usually indolent and
often a consequence of chronic antigenic stimulation from a pathogen such as Helicobacter …
often a consequence of chronic antigenic stimulation from a pathogen such as Helicobacter …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
AKS Salama, S Li, ER Macrae, JI Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …
KRAS: From undruggable to a druggable Cancer Target
D Uprety, AA Adjei - Cancer treatment reviews, 2020 - Elsevier
RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …
cancer testing has highlighted the importance and potential benefits of standardizing the …
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders
C Kornauth, T Pemovska, GI Vladimer, G Bayer… - Cancer discovery, 2022 - AACR
Personalized medicine aims to match the right drug with the right patient by using specific
features of the individual patient's tumor. However, current strategies of personalized …
features of the individual patient's tumor. However, current strategies of personalized …
[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
Mutations driving CLL and their evolution in progression and relapse
Which genetic alterations drive tumorigenesis and how they evolve over the course of
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …